Sigyn Therapeutics, Inc.
SIGY· OTC
SIGYSigyn Therapeutics, Inc.
Filed Apr 6, 2021 · 10-K · 96 days after period end · 0001493152-21-008047
derived · Computed from the longer spans the company filed.
| Metric | Q4 2020dderived from reported figures | Q4 2019 | Q4 2018dderived from reported figures | Q4 2017dderived from reported figures |
|---|---|---|---|---|
| Revenue | — | $5.34K | — | — |
| Net Income | -$840.18K | -$1.55K | -$1.22M | -$1.17M |
| EPS Diluted | — | $0.00 | — |
Sigyn Therapeutics, Inc. · CIK 1642159 · Engraved from SEC EDGAR
| — |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2020 · filed Apr 6, 2021 · 96 d after period end
